HF
CRSP icon

HRT Financial’s CRISPR Therapeutics CRSP Stock Holding History

HRT Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.34M Buy
134,664
+64,132
+91% +$3.38M 0.01% 932
2026
Q1 		$3.35M Buy
70,532
+42,560
+152% +$2.24M 0.01% 1247
2025
Q4 		$1.47M Buy
+27,972
New +$1.68M ﹤0.01% 1498
2025
Q2 		– Sell
-90,915
Closed -$3.09M – 2765
2025
Q1 		$3.09M Buy
90,915
+82,277
+953% +$3.49M 0.02% 624
2024
Q4 		$339K Buy
+8,638
New +$408K ﹤0.01% 1648
2024
Q2 		– Sell
-69,429
Closed -$4.73M – 2355
2024
Q1 		$4.73M Buy
+69,429
New +$4.97M 0.03% 276
2023
Q3 		– Sell
-14,093
Closed -$791K – 2502
2023
Q2 		$791K Sell
14,093
-21,391
-60% -$1.21M 0.01% 1094
2023
Q1 		$1.6M Buy
35,484
+21,400
+152% +$1.04M 0.02% 715
2022
Q4 		$572K Buy
+14,084
New +$747K 0.01% 1322
2021
Q3 		– Sell
-101,731
Closed -$16.5M – 3355
2021
Q2 		$16.5M Buy
101,731
+91,222
+868% +$11.1M 0.15% 113
2021
Q1 		$1.28M Buy
+10,509
New +$1.59M 0.01% 917
2020
Q3 		– Sell
-3,766
Closed -$276K – 1961
2020
Q2 		$276K Buy
+3,766
New +$220K 0.01% 1022
2019
Q1 		– Sell
-10,381
Closed -$296K – 564
2018
Q4 		$296K Buy
+10,381
New +$361K 0.04% 358

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HRT Financial's CRSP Position: Q2 2026 in Review

HRT Financial increased its CRISPR Therapeutics (CRSP) stake by 91% in Q2 2026, buying an estimated $3.38M and bringing the position to 134,664 shares worth $7.34M. The position accounts for 0.01% of the portfolio, ranked #932.

HRT Financial first reported a position in CRSP in Q4 2018 and has held it in 13 quarters since. The position peaked at $16.5M in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • HRT Financial held 134,664 shares of CRISPR Therapeutics worth $7.34M as of Q2 2026.
  • HRT Financial bought 64,132 CRISPR Therapeutics shares in Q2 2026, an estimated $3.38M.
  • CRISPR Therapeutics made up 0.01% of HRT Financial's portfolio in Q2 2026, its #932 holding.
  • HRT Financial first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 13 quarters since.
  • HRT Financial's CRISPR Therapeutics position peaked at $16.5M in Q2 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.